- Home
- RADX vs ARTV Comparison
RADX vs ARTV Comparison
Compare RADX & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- ARTV
- Stock Information
- Founded
- RADX 2021
- ARTV 2019
- Country
- RADX Australia
- ARTV United States
- Employees
- RADX N/A
- ARTV N/A
- Industry
- RADX
- ARTV
- Sector
- RADX
- ARTV
- Exchange
- RADX NYSE
- ARTV NYSE
- Market Cap
- RADX 32.5M
- ARTV 39.0M
- IPO Year
- RADX N/A
- ARTV 2024
- Fundamental
- Price
- RADX $4.25
- ARTV $2.04
- Analyst Decision
- RADX Strong Buy
- ARTV Strong Buy
- Analyst Count
- RADX 2
- ARTV 8
- Target Price
- RADX $13.50
- ARTV $18.14
- AVG Volume (30 Days)
- RADX 22.4K
- ARTV 366.6K
- Earning Date
- RADX 02-26-2025
- ARTV 08-28-2025
- Dividend Yield
- RADX N/A
- ARTV N/A
- EPS Growth
- RADX N/A
- ARTV N/A
- EPS
- RADX N/A
- ARTV N/A
- Revenue
- RADX $204,609.00
- ARTV N/A
- Revenue This Year
- RADX N/A
- ARTV N/A
- Revenue Next Year
- RADX N/A
- ARTV N/A
- P/E Ratio
- RADX N/A
- ARTV N/A
- Revenue Growth
- RADX N/A
- ARTV N/A
- 52 Week Low
- RADX $3.50
- ARTV $1.47
- 52 Week High
- RADX $50.82
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- ARTV N/A
- Support Level
- RADX N/A
- ARTV N/A
- Resistance Level
- RADX N/A
- ARTV N/A
- Average True Range (ATR)
- RADX 0.00
- ARTV 0.00
- MACD
- RADX 0.00
- ARTV 0.00
- Stochastic Oscillator
- RADX 0.00
- ARTV 0.00
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).